The College of Nursing, Zhejiang Chinese Medical University, Hangzhou 310053, China.
The First Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou 310053, China.
J Immunol Res. 2020 Jul 11;2020:2383970. doi: 10.1155/2020/2383970. eCollection 2020.
Constipation, a gastrointestinal function disorder, is one of the side effects of paclitaxel (PTX) chemotherapy. Shenhuang plaster (SHP) application on the Shenque acupoint promotes gut motility in clinical settings. In this study, we elucidated the ingredients in SHP and evaluated its effects on PTX-induced constipation using a tumour-bearing mouse model. SHP was prepared using the traditional Chinese plaster preparation method. The ingredients were analysed using UPLC-MS/MS and identified via screening in a standard drug database. The gastrointestinal transit was evaluated by the movement of a fluorescein-labelled dextran in the gastrointestinal tract. A histological study of the mucosa was carried out after haematoxylin and eosin staining. mRNA expression was assessed using real-time RT-PCR, and the foetal microbiota composition was elucidated through 16 s rDNA sequencing and BLAST analysis. Our results indicate that the application of SHP attenuated weight gain inhibition by PTX; however, no inhibitory effect was observed on tumour growth. PTX-induced sluggish intestine, villus, and mucosal base layer damage were significantly improved following the application of SHP. Further, SHP enhanced the stimulation efficiency of PTX on TLR4 and its downstream cytokines, as well as on IL-1 in intestinal cells. SHP combined with PTX reshaped the microbiota, which showed beneficial effects on health. Hence, these results provide evidence that SHP alleviates PTX-induced constipation and intestinal morphological damage but augments the effects of PTX on the expression of cytokines in the TLR4 pathway and IL-1. Therefore, we propose that SHP stimulates the host immune response to eradicate cancer cells.
便秘是紫杉醇(PTX)化疗的副作用之一,是一种胃肠道功能紊乱。神阙穴敷贴神黄膏可促进临床肠道蠕动。本研究采用 UPLC-MS/MS 分析和标准药物数据库筛选的方法阐明神黄膏的成分,并采用荷瘤小鼠模型评估其对 PTX 诱导的便秘的作用。神黄膏采用传统的中药膏剂制备方法制备。采用 UPLC-MS/MS 分析和标准药物数据库筛选的方法分析成分。通过胃肠道中荧光素标记的葡聚糖的运动来评估胃肠转运。通过苏木精和伊红染色进行胃黏膜组织学研究。采用实时 RT-PCR 评估 mRNA 表达,并通过 16s rDNA 测序和 BLAST 分析阐明胎儿微生物群的组成。我们的结果表明,神黄膏的应用减轻了 PTX 引起的体重增加抑制;然而,对肿瘤生长没有抑制作用。神黄膏的应用显著改善了 PTX 引起的肠蠕动缓慢、绒毛和黏膜基底层损伤。此外,神黄膏增强了 PTX 对 TLR4 及其下游细胞因子以及肠细胞中 IL-1 的刺激效率。神黄膏联合 PTX 重塑了微生物群,对健康有益。因此,这些结果表明神黄膏减轻了 PTX 诱导的便秘和肠道形态损伤,但增强了 TLR4 途径中细胞因子和 IL-1 的表达对 PTX 的作用。因此,我们提出神黄膏刺激宿主免疫反应以消灭癌细胞。